山东医药2016，Vol.56Issue(11)：8-10,3.DOI:10.3969/j.issn.1002-266X.2016.11.003
Akt抑制剂与利妥昔单抗联合应用对伯基特淋巴瘤细胞株Daudi增殖及凋亡的影响
Effects of Akt inhibitor combined with rituximab on proliferation and apoptosis of Burkitt′s lymphoma cell line Daudi
摘要
Abstract
Objective To investigate the effect of Akt inhibitor (AZD5363) combined with rituximab on cell prolifer-ation and apoptosis of Burkitt′s lymphoma (BL) Daudi cells in vitro, and to explore its mechanism.Methods Human BL Daudi cells were cultured and then were divided into four groups:the control group (treated by 1640 culture medium with fetal bovine serum) , AZD5363 group (treated by 40 μmol/L AZD5363) , rituximab group (treated by 50 μg/mL ritux-imab) and the combination group (treated by 40 μmol/L AZD5363 +50 μg/mL rituximab).They were all put into the incubator for 24-72 h.The growth inhibition and apoptosis rate of Daudi cells were detected by CCK-8 colorimetry and flow cytometer respectively.In addition, the expression of phosphorylated Akt (p-Akt) and total Akt (T-Akt) was detected by Western blotting.Results The growth inhibition rate of the combination group after 24, 48 and 72 h was significantly in-creased as compared with that of the AZD5363 and rituximab groups (all P＜0.05).The difference of apoptosis rate among the control group and AZD5363 group, rituximab group and the combination group was statistically significant after 48 and 72 h, and the apoptosis rate in the combination group was higher than those of the AZD 5363 and rituximab group after 48 and 72 h (all P＜0.05).The expression of p-Akt in the control group, AZD5363 group, rituximab group and the combina-tion group were respectively 0.59 ±0.06, 0.33 ±0.03, 0.45 ±0.04 and 0.18 ±0.04 after 24 h, and the difference of ex-pression of p-Akt was statistically significant among the control group and experimental groups , between AZD5363 group and the combination group, between the combination group and AZD5363 group, rituximab group (all P＜0.05).Conclu-sions AZD5363 in combination with rituximab can significantly inhibit cell proliferation and promote the apoptosis of BL Daudi cells.Inhibition of Akt phosphorylation and blocking of PI 3k/Akt signal transduction pathway may be the mechanism of its antitumor effect .关键词
伯基特淋巴瘤/Daudi细胞/利妥昔单抗/磷酸化AktKey words
Burkitt's lymphoma/Daudi cells/rituximab/phosphorylated Akt分类
临床医学引用本文复制引用
杨玉婷,谭晓虹,岑洪..Akt抑制剂与利妥昔单抗联合应用对伯基特淋巴瘤细胞株Daudi增殖及凋亡的影响[J].山东医药,2016,56(11):8-10,3.基金项目
国家自然科学基金资助项目(81160298) （81160298）
广西医疗卫生适宜技术研究与开发课题(S201301-02). （S201301-02）
